Nycomed finds a US partner for asthma drug
The decision by Sepracor to in-license the US marketing rights to inhaled corticosteroid Alvesco caps a four-year commercial and regulatory odyssey for the asthma drug.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.